Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBT (2020 - 2025)

Historic EBT for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $4.7 million.

  • Bioventus' EBT rose 18880.02% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 12426.72%. This contributed to the annual value of -$49.1 million for FY2024, which is 5943.72% up from last year.
  • According to the latest figures from Q3 2025, Bioventus' EBT is $4.7 million, which was up 18880.02% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' EBT registered a high of $24.5 million during Q2 2021, and its lowest value of -$130.6 million during Q4 2022.
  • Its 5-year average for EBT is -$17.8 million, with a median of -$5.5 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first crashed by 404338.31% in 2022, then surged by 18880.02% in 2025.
  • Quarter analysis of 5 years shows Bioventus' EBT stood at -$2.8 million in 2021, then plummeted by 1079.64% to -$32.4 million in 2022, then soared by 74.09% to -$8.4 million in 2023, then skyrocketed by 137.63% to $3.2 million in 2024, then soared by 47.64% to $4.7 million in 2025.
  • Its last three reported values are $4.7 million in Q3 2025, $10.3 million for Q2 2025, and -$3.4 million during Q1 2025.